C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer (Q43901429)

27 November 2017

title

C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer (English)

1 reference

27 November 2017

1 reference

1 reference

1 reference

14

C Blomqvist

1 reference

27 November 2017

J Sjöström

1

1 reference

27 November 2017

J Collan

2

1 reference

27 November 2017

K von Boguslawski

3

1 reference

27 November 2017

K Franssila

4

1 reference

27 November 2017

N-O Bengtsson

5

1 reference

27 November 2017

I Mjaaland

6

1 reference

27 November 2017

P Malmström

7

1 reference

27 November 2017

B Østenstad

8

1 reference

27 November 2017

E Wist

9

1 reference

27 November 2017

V Valvere

10

1 reference

27 November 2017

J Bergh

11

1 reference

27 November 2017

D Skiöld-Petterson

12

1 reference

27 November 2017

E Saksela

13

1 reference

27 November 2017

publication date

1 March 2002

1 reference

European Journal of Cancer

27 November 2017

published in

1 reference

27 November 2017

volume

38

1 reference

27 November 2017

issue

4

1 reference

27 November 2017

page(s)

535-542

1 reference

Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene

27 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure: a randomised phase III study with crossover on progression by the Scandinavian Breast Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

HER-2/neu in node-negative breast cancer: prognostic significance of overexpression influenced by the presence of in situ carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumour in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Prediction of response to primary chemotherapy for operable breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

Improving the quality of reporting of randomized controlled trials. The CONSORT statement

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2801%2900403-8

7 January 2021

10.1016/S0959-8049(01)00403-8

Identifiers

DOI

1 reference

27 November 2017

1 reference